Oraya Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.orayainc.com
Iray for Vascularized Pigment Epithelial Detachment (VPED) Secondary to Age Related Macular Degeneration
Not Applicable
- Conditions
- Retinal Pigment Epithelial Detachment With VascularizationAge Related Macular Degeneration
- Interventions
- Radiation: Iray
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2012-10-25
- Lead Sponsor
- Oraya Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01521819
- Locations
- 🇮🇹
Università Vita-Salute Istituto Scientifico San Raffaele, Milano, Italy
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Phase 2
- Conditions
- Age-Related Macular DegenerationWet Macular DegenerationMacular DegenerationEye DiseasesRetinal Diseases
- Interventions
- Device: IRay
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Oraya Therapeutics, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT01521065
- Locations
- 🇬🇧
Manchester Royal Eye Hospital, Manchester, United Kingdom
IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD
Not Applicable
- Conditions
- Polypoidal Chorodial VasculopathyAge Related Macular Degeneration
- Interventions
- Radiation: Iray
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- Oraya Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01516294
- Locations
- 🇮🇹
Università Vita-Salute Istituto Scientifico San Raffaele, Milano, Italy
Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)
Not Applicable
Withdrawn
- Conditions
- Wet Age-related Macular DegenerationAge-related Macular DegenerationWet AMDMacular DegenerationAMD
- Interventions
- Device: IRay
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2011-12-30
- Lead Sponsor
- Oraya Therapeutics, Inc.
- Registration Number
- NCT01339949
- Locations
- 🇬🇧
Manchester Royal Eye Hospital, Manchester, United Kingdom
🇬🇧King's College Hospital, London, United Kingdom
🇮🇹Università Vita-Salute Istituto Scientifico San Raffaele, Milan, Italy
Safety & Tolerability of the IRay System in Subjects With Exudative Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Phase 1
- Conditions
- Age-Related Macular DegenerationWet Age-Related Macular DegenerationMacular DegenerationEye DiseasesRetinal Diseases
- Interventions
- Device: IRay
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Oraya Therapeutics, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT01217762
- Locations
- 🇲🇽
Asociación Para Evitar la Ceguera en México, I.A.P., Mexico Distrito Federal, Delegación Coyoacán, Mexico
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
Phase 2
Completed
- Conditions
- Macular DegenerationEye DiseasesWet Age-Related Macular DegenerationRetinal DiseasesWet AMDAge-Related Macular DegenerationAMD
- Interventions
- Device: IRay
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Oraya Therapeutics, Inc.
- Target Recruit Count
- 230
- Registration Number
- NCT01016873
- Locations
- 🇬🇧
Royal Victoria Hospital, Belfast, United Kingdom
🇬🇧Torbay Hospital, Devon, United Kingdom
🇬🇧King's College, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath